Anaplastic oligoastrocytoma
disease diseaseOn this page
Also known as aMOAanaplastic mixed gliomaAOASTWHO grade III mixed glioma
Summary
Anaplastic oligoastrocytoma (MONDO:0016703) is a disease and 32 clinical trials. Top therapeutic interventions include mannitol, sorbitol, and temozolomide. A subtype of malignant mixed neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 32
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | anaplastic oligoastrocytoma |
| Mondo ID | MONDO:0016703 |
| EFO | EFO:0002500 |
| Orphanet | 251663 |
| NCIT | C6959 |
| UMLS | C0431108 |
| MedGen | 96556 |
| GARD | 0010637 |
| Is cancer (heuristic) | no |
Also known as: aMOA · anaplastic mixed glioma · anaplastic oligoastrocytoma · AOAST · WHO grade III mixed glioma
Data availability: 1 cell line.
Disease family
This is a subtype of malignant mixed neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mixed neoplasm › anaplastic oligoastrocytoma
Related subtypes (14): carcinoma ex pleomorphic adenoma, uterine body mixed cancer, carcinosarcoma, adenocarcinofibroma, ovarian seromucinous carcinoma, adenosarcoma, Wilms tumor, combined lung carcinoma, mixed lobular and ductal breast carcinoma, gonadoblastoma, malignant mixed epithelial stromal tumor of the kidney, malignant phyllodes tumor, malignant vaginal mixed epithelial and mesenchymal neoplasm, adenoacanthoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 32.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 15 |
| PHASE2 | 5 |
| Not specified | 5 |
| PHASE3 | 4 |
| PHASE1/PHASE2 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01656980 | PHASE3 | UNKNOWN | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma |
| NCT01765088 | PHASE3 | UNKNOWN | A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas |
| NCT02629757 | PHASE3 | UNKNOWN | A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas |
| NCT05600491 | PHASE3 | UNKNOWN | A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme |
| NCT02800486 | PHASE2 | RECRUITING | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA |
| NCT03180502 | PHASE2 | ACTIVE_NOT_RECRUITING | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma |
| NCT04623931 | PHASE2 | RECRUITING | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas |
| NCT00303849 | PHASE1/PHASE2 | COMPLETED | Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors |
| NCT01189266 | PHASE1/PHASE2 | COMPLETED | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma |
| NCT01380782 | PHASE2 | COMPLETED | BIBF 1120 for Recurrent High-Grade Gliomas |
| NCT01721577 | PHASE1/PHASE2 | TERMINATED | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas |
| NCT01847235 | PHASE2 | COMPLETED | Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial |
| NCT02192359 | PHASE1 | ACTIVE_NOT_RECRUITING | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas |
| NCT00884416 | PHASE1 | COMPLETED | Sorafenib in Newly Diagnosed High Grade Glioma |
| NCT01144247 | PHASE1 | COMPLETED | Cellular Immunotherapy Study for Brain Cancer |
| NCT01156584 | PHASE1 | COMPLETED | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma |
| NCT01250470 | PHASE1 | COMPLETED | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma |
| NCT01392209 | PHASE1 | COMPLETED | Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma |
| NCT01470794 | PHASE1 | COMPLETED | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor |
| NCT01522820 | PHASE1 | COMPLETED | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors |
| NCT01922076 | PHASE1 | COMPLETED | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas |
| NCT01985256 | PHASE1 | COMPLETED | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor |
| NCT02015819 | PHASE1 | COMPLETED | Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas |
| NCT02026271 | PHASE1 | COMPLETED | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma |
| NCT02168270 | PHASE1 | TERMINATED | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma |
| NCT03043391 | PHASE1 | COMPLETED | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children |
| NCT03072134 | PHASE1 | COMPLETED | Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma |
| NCT00035373 | Not specified | TERMINATED | Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols |
| NCT01637753 | Not specified | UNKNOWN | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma |
| NCT01711580 | Not specified | WITHDRAWN | Re-irradiation of High Grade Gliomas: a Quality of Life Study |
| NCT01849952 | Not specified | TERMINATED | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas |
| NCT02795364 | Not specified | UNKNOWN | Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma Gliomas |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MANNITOL | 4 | 2 |
| SORBITOL | 4 | 2 |
| TEMOZOLOMIDE | 4 | 2 |
| CARMUSTINE | 4 | 1 |
| ETOPOSIDE PHOSPHATE | 4 | 1 |
| FLUCYTOSINE | 4 | 1 |
| NINTEDANIB | 4 | 1 |
| SODIUM THIOSULFATE | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| ADAVOSERTIB | 2 | 1 |
| AXL-1717 | 2 | 1 |
| VELEDIMEX | 2 | 1 |
| VOCIMAGENE AMIRETROREPVEC | 2 | 1 |
| CHEMBL4228794 | 0 | 2 |
| CHEMBL4248195 | 0 | 2 |
| CHEMBL3753202 | 0 | 1 |